Showing results (311-320 of 542) with videos related to
Sort By:
Pageof 55
Pathology, Research and Practice|January 22, 2025
Intra-patient comparison of microarchitecture of tumour negative lymph nodes from oesophageal cancer patients - Results from the MRC Oe02 trialMaximilian Kloft, Elzbieta Budginaite, Sander M J van Kuijk, et al.BJS Open|February 23, 2022
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched studyOsama Moussa, Ricky Harminder Bhogal, George Malietzis, et al.Journal of the National Cancer Institute|October 30, 2012
Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancerArnaud D Roth, Mauro Delorenzi, Sabine Tejpar, et al.Cancer Biotherapy & Radiopharmaceuticals|April 22, 2021
227Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I StudyOla Lindén, Andrew T Bates, David Cunningham, et al.The Oncologist|May 7, 2017
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant ChemoradiotherapyFrancesco Sclafani, Gina Brown, David Cunningham, et al.Clinical Pharmacokinetics|September 6, 2015
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic MalignanciesElodie Odore, François Lokiec, Esteban Cvitkovic, et al.World Journal of Nuclear Medicine|July 22, 2022
The Diagnostic Accuracy of 18 F-FGD-PET/CT for Cancer of the Gallbladder: A Retrospective StudyStephanos Pericleous, Sophie L F Doran, Andrew Wotherspoon, et al.International Journal of Radiation Oncology, Biology, Physics|June 3, 2015
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C TrialFrancesco Sclafani, Clare Peckitt, David Cunningham, et al.Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 28, 2020
Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trialNaser Davarzani, Lindsay C Hewitt, Matthew D Hale, et al.European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancerIan Chau, Andrew R Norman, David Cunningham, et al.Pageof 55